Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML.
Roas M, Vick B, Kasper MA, Able M, Polzer H, Gerlach M, Kremmer E, Hecker JS, Schmitt S, Stengl A, Waller V, Hohmann N, Festini M, Ludwig A, Rohrbacher L, Herold T, Subklewe M, Götze KS, Hackenberger CPR, Schumacher D, Helma-Smets J, Jeremias I, Leonhardt H, Spiekermann K.
Roas M, et al. Among authors: kremmer e.
Blood. 2023 Mar 2;141(9):1023-1035. doi: 10.1182/blood.2021015246.
Blood. 2023.
PMID: 35981498
Free article.